Deals channel feed

Crushed by a tri­al fail­ure, Tokai hands the reins — and the stock list­ing — to Ot­ic

9 years ago

Wait a sec­ond. J&J is back in the bid­ding for Acte­lion, el­bow­ing Sanofi aside

9 years ago

Sum­it­o­mo Dainip­pon beefs up on­col­o­gy pipeline with $780M Tolero buy­out

9 years ago

Can Sanofi push a CVR on Acte­lion af­ter the Lem­tra­da fi­as­co?

9 years ago

Al­ler­gan’s deal spree con­tin­ues with $2.9B Life­Cell buy­out

9 years ago

Stiff-armed by a stub­born Acte­lion, J&J takes its check book and walks away, leav­ing an open­ing for Sanofi

9 years ago

Cel­gene buys Acety­lon, keeps what it wants and spins the rest back out as Re­ge­na­cy

9 years ago

Will J&J come up with a big enough trea­sure trove to win an Acte­lion buy­out?

9 years ago
R&D
Pharma

That En­gMab buy­out? Cel­gene agreed to pay up to $3B for BC­MA-tar­get­ing drug

9 years ago

AS­CO star, backed by bil­lion­aires, goes to Astel­las in $1.4 bil­lion buy­out

9 years ago

Al­ler­gan’s ex­ec­u­tive team or­ches­trates a $200M buy­out to beef up gas­troen­terol­o­gy pipeline

9 years ago

To­bi­ra chair­man’s din­ner with Brent: In­dus­try chat led to a 3-month pur­suit and a stun­ning $1.7B deal

9 years ago

Scoop: Cel­gene tar­gets a cure for myelo­ma/lym­phoma with $600M En­gMab buy­out

9 years ago

An ac­quis­i­tive Cel­gene looks ready to pop a new mul­ti­ple myelo­ma deal

9 years ago

So Take­da wants to do up to $20B in M&A? Wel­come to the bid­ding war for US biotechs

9 years ago

Cel­gene pays $50M to tie up with four big can­cer re­search cen­ters

9 years ago
Pharma
First page Previous page 113114115116
A service from the Financial Times